Literature DB >> 21436639

Application of pharmacogenetics: UGT1A1*28 and nilotinib-induced unconjugated hyperbilirubinaemia in a patient with chronic myeloid leukaemia.

Sammy Pak-lam Chen, Wing-tat Poon, Chloe Miu Mak, Ching-wan Lam, Yok-lam Kwong, Albert Yan-wo Chan, Sidney Tam.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21436639     DOI： 10.1097/PAT.0b013e328343f0b4

Source DB:  PubMed          Journal:  Pathology        ISSN： 0031-3025            Impact factor:   5.306


× No keyword cloud information.
  4 in total

1.  Nilotinib-induced liver injury: A case report.

Authors:  Youwen Tan; Yun Ye; Xingbei Zhou
Journal:  Medicine (Baltimore)       Date:  2020-09-04       Impact factor: 1.889

2.  Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.

Authors:  Muhammad Wasif Saif; Melissa Hennessey Smith; Antonia Maloney; Robert B Diasio
Journal:  Ann Gastroenterol       Date:  2016-06-10

3.  Inhibitory effects of UDP-glucuronosyltransferase (UGT) typical ligands against E. coli beta-glucuronidase (GUS).

Authors:  Ling Xiao; Dehui Chi; Guiju Sheng; Wenjuan Li; Penghui Lin; Sicheng Liang; Liangliang Zhu; Peipei Dong
Journal:  RSC Adv       Date:  2020-06-16       Impact factor: 3.361

Review 4.  UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation.

Authors:  Ryan S Nelson; Nathan D Seligson; Sal Bottiglieri; Estrella Carballido; Alex Del Cueto; Iman Imanirad; Richard Levine; Alexander S Parker; Sandra M Swain; Emma M Tillman; J Kevin Hicks
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.